ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Molecular Partners AG Investors Suffering Losses Greater Than $100,000 to Find Counsel Before Important Deadline in Securities Class Action

NEW YORK, August 10, 2022 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Molecular Partners AG (NASDAQ: MOLN) securities: (i) pursuant to and/or traceable to the offering documents issued pursuant to the initial public offering of the Company carried out on or June 16, 2021 (the “IPO”); and/or (ii) between June 16, 2021 and April 26, 2022both dates included (the “Class Period”), of the material September 12, 2022 lead applicant deadline.

SO WHAT: If you have purchased securities from Molecular Partners, you may be entitled to compensation without payment of fees or out-of-pocket costs through a contingent fee arrangement.

WHAT TO DO NEXT: To join the Molecular Partners class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] Where [email protected] for more information on the class action. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court not later than September 12, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified attorneys with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually handle securities class action lawsuits, but are merely middlemen who refer clients or partner with law firms that actually litigate the cases. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company obtained more than $438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as a Titan of the Plaintiffs Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the IPO documents were negligently prepared and, as a result, contained misrepresentations of material facts or failed to state other facts necessary for the statements made not to be misleading and were not not prepared in accordance with the rules and regulations governing their preparation. Further, the Complaint alleges that, throughout the Class Period, the Defendants made materially false and misleading statements regarding the company’s business, operations and prospects. Specifically, the IPO Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (1) ensovibep was less effective in treating COVID-19 than Defendants had led investors to believe; (2) therefore, the United States Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting emergency use authorization ( “USA”); (3) the decline in global rates of COVID-19 has significantly reduced the Company’s chances of obtaining an EUA for ensovibep; (4) as a product candidate, MP0310 (AMG 506), in development for the treatment of certain types of cancer, was less attractive to Amgen Inc. (“Amgen”) than the defendants had led investors to believe ; (5) as a result, there was a strong likelihood that Amgen would return the worldwide rights to MP0310 to Molecular Partners; (6) because of all of the above, the clinical and commercial prospects of ensovibep and MP0310 have been overestimated; and (7) as a result, the IPO Documents and the Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to provide the information that should be contained therein. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the Molecular Partners class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] Where [email protected] for more information on the class action.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firmon Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, Pennsylvania

About the author